Cytokinetics, Incorporated (NASDAQ:CYTK) Director John T. Henderson Sells 3,190 Shares

Cytokinetics, Incorporated (NASDAQ:CYTK) Director John T. Henderson sold 3,190 shares of Cytokinetics stock in a transaction on Tuesday, April 15th. The stock was sold at an average price of $38.66, for a total transaction of $123,325.40. Following the completion of the transaction, the director now directly owns 66,348 shares in the company, valued at $2,565,013.68. This represents a 4.59 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Cytokinetics Price Performance

NASDAQ:CYTK opened at $39.15 on Thursday. The company has a debt-to-equity ratio of 5.93, a current ratio of 9.28 and a quick ratio of 9.28. The company has a 50 day moving average price of $42.73 and a 200-day moving average price of $47.93. Cytokinetics, Incorporated has a 1-year low of $32.74 and a 1-year high of $69.90. The firm has a market cap of $4.67 billion, a price-to-earnings ratio of -7.28 and a beta of 0.94.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.03. The firm had revenue of $16.93 million during the quarter, compared to analysts’ expectations of $14.26 million. Equities research analysts forecast that Cytokinetics, Incorporated will post -5.24 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on CYTK. Needham & Company LLC restated a “buy” rating and set a $72.00 target price on shares of Cytokinetics in a research note on Tuesday, April 8th. JMP Securities reaffirmed a “market outperform” rating and issued a $78.00 price objective on shares of Cytokinetics in a research report on Thursday, April 10th. Stifel Nicolaus assumed coverage on shares of Cytokinetics in a research report on Wednesday, January 22nd. They set a “buy” rating and a $80.00 target price on the stock. Evercore ISI upgraded shares of Cytokinetics to a “strong-buy” rating in a research note on Friday, February 7th. Finally, Morgan Stanley set a $67.00 target price on Cytokinetics in a research report on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Cytokinetics has an average rating of “Moderate Buy” and a consensus price target of $81.63.

Hedge Funds Weigh In On Cytokinetics

Large investors have recently bought and sold shares of the business. Fifth Third Bancorp grew its holdings in Cytokinetics by 42.2% in the first quarter. Fifth Third Bancorp now owns 981 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 291 shares during the period. GAMMA Investing LLC grew its stake in Cytokinetics by 281.0% in the 1st quarter. GAMMA Investing LLC now owns 1,120 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 826 shares during the period. Harbor Capital Advisors Inc. grew its stake in Cytokinetics by 17.7% in the 1st quarter. Harbor Capital Advisors Inc. now owns 53,113 shares of the biopharmaceutical company’s stock valued at $2,135,000 after acquiring an additional 7,983 shares during the period. UMB Bank n.a. increased its holdings in Cytokinetics by 91.4% in the 1st quarter. UMB Bank n.a. now owns 1,156 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 552 shares in the last quarter. Finally, E. Ohman J or Asset Management AB acquired a new position in Cytokinetics during the first quarter worth $13,232,000.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.